S Beard

1.8k total citations
39 papers, 1.3k citations indexed

About

S Beard is a scholar working on Psychiatry and Mental health, Economics and Econometrics and Pharmacology. According to data from OpenAlex, S Beard has authored 39 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 10 papers in Economics and Econometrics and 8 papers in Pharmacology. Recurrent topics in S Beard's work include Health Systems, Economic Evaluations, Quality of Life (10 papers), Atrial Fibrillation Management and Outcomes (4 papers) and Schizophrenia research and treatment (4 papers). S Beard is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (10 papers), Atrial Fibrillation Management and Outcomes (4 papers) and Schizophrenia research and treatment (4 papers). S Beard collaborates with scholars based in United Kingdom, United States and Germany. S Beard's co-authors include Amanda Hunn, Jeremy Wight, Fiona Sampson, Anke Richter, John M. Kane, Patricia Thieda, Evelina A. Zimovetz, Paul Tappenden, R. Geoff Richards and Sorrel Wolowacz and has published in prestigious journals such as Journal of the American College of Cardiology, Annals of Surgery and British Journal of Cancer.

In The Last Decade

S Beard

39 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S Beard United Kingdom 19 276 265 251 206 187 39 1.3k
Susan D. Ross United States 21 414 1.5× 82 0.3× 184 0.7× 51 0.2× 226 1.2× 35 1.9k
A.L.M. Verbeek Netherlands 26 542 2.0× 269 1.0× 386 1.5× 87 0.4× 186 1.0× 62 3.0k
Olivier Guérin France 26 222 0.8× 379 1.4× 137 0.5× 106 0.5× 43 0.2× 114 2.2k
Samuel Whittle Australia 24 310 1.1× 97 0.4× 82 0.3× 53 0.3× 86 0.5× 94 1.6k
Helen Rodgers United Kingdom 19 205 0.7× 161 0.6× 263 1.0× 118 0.6× 51 0.3× 45 2.9k
Patrícia Caetano Canada 21 745 2.7× 130 0.5× 491 2.0× 63 0.3× 873 4.7× 32 2.0k
Angela Juby Canada 22 592 2.1× 171 0.6× 103 0.4× 49 0.2× 713 3.8× 55 1.6k
Stacey S. Cofield United States 31 419 1.5× 158 0.6× 734 2.9× 230 1.1× 24 0.1× 81 3.2k
Gillian C. Hall United Kingdom 20 252 0.9× 357 1.3× 279 1.1× 310 1.5× 15 0.1× 48 1.8k
Alan Oglesby United States 25 371 1.3× 27 0.1× 88 0.4× 292 1.4× 233 1.2× 55 2.2k

Countries citing papers authored by S Beard

Since Specialization
Citations

This map shows the geographic impact of S Beard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Beard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Beard more than expected).

Fields of papers citing papers by S Beard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Beard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Beard. The network helps show where S Beard may publish in the future.

Co-authorship network of co-authors of S Beard

This figure shows the co-authorship network connecting the top 25 collaborators of S Beard. A scholar is included among the top collaborators of S Beard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Beard. S Beard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Reddy, Vivek Y., Ron Akehurst, Stacey L. Amorosi, et al.. (2015). Cost effectiveness of left atrial appendage closure versus Warfarin for stroke risk reduction in non-valvular Atrial Fibrillation in CMS patients. Value in Health. 18(3). A44–A44. 1 indexed citations
3.
Shields, Gemma & S Beard. (2015). A Systematic Review of the Economic and Humanistic Burden of Gout. PharmacoEconomics. 33(10). 1029–1047. 49 indexed citations
4.
Beard, S, et al.. (2013). Direct healthcare costs of glaucoma treatment. British Journal of Ophthalmology. 97(6). 720–724. 20 indexed citations
5.
Zimovetz, Evelina A., Juliana Setyawan, S Beard, & P. Hodgkins. (2012). PMH37 Systematic Review of Health State Utilities in Attention Deficit Hyperactivity Disorder (ADHD). Value in Health. 15(7). A340–A340. 2 indexed citations
6.
Zimovetz, Evelina A., et al.. (2012). PRS18 Systematic Review of Economic Evaluations, Utility Estimates, Resource Utilisation, and Costs in Chronic Idiopathic Urticaria. Value in Health. 15(7). A562–A562. 1 indexed citations
7.
McLellan, A. R., Sorrel Wolowacz, Evelina A. Zimovetz, et al.. (2011). Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporosis International. 22(7). 2083–2098. 182 indexed citations
8.
Gutiérrez, Lia, Neil Roskell, Jordi Castellsagué, et al.. (2011). Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom. Journal of Medical Economics. 14(1). 99–107. 33 indexed citations
9.
Roskell, Neil, S Beard, Yang Zhao, & Trong Kim Le. (2010). A Meta‐Analysis of Pain Response in the Treatment of Fibromyalgia. Pain Practice. 11(6). 516–527. 35 indexed citations
10.
Samuel, Miny, Evelina A. Zimovetz, Zahava Gabriel, & S Beard. (2010). Efficacy and safety of treatments for refractory generalized anxiety disorder. International Clinical Psychopharmacology. 26(2). 63–68. 22 indexed citations
11.
Wolowacz, Sorrel, S Beard, Paul A. Robinson, et al.. (2009). Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clinical Therapeutics. 31(1). 194–212. 61 indexed citations
12.
Beard, S, et al.. (2007). Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Current Medical Research and Opinion. 24(2). 385–399. 22 indexed citations
13.
Beard, S, et al.. (2006). A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. The European Journal of Health Economics. 7(3). 165–172. 18 indexed citations
14.
Legendre, Christophe, S Beard, Anne Crochard, et al.. (2005). The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. The European Journal of Health Economics. 6(2). 172–182. 9 indexed citations
15.
Beard, S, Amanda Hunn, & Jeremy Wight. (2003). Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technology Assessment. 7(40). iii, ix–x, 1. 216 indexed citations
16.
Thieda, Patricia, S Beard, Anke Richter, & John M. Kane. (2003). An Economic Review of Compliance With Medication Therapy in the Treatment of Schizophrenia. Psychiatric Services. 54(4). 508–516. 144 indexed citations
17.
Beard, S, et al.. (2001). An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. Journal of Medical Economics. 4(1-4). 199–204. 3 indexed citations
18.
Beard, S, Paul Lorigan, & Fiona Sampson. (2000). The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin’s disease and non-Hodgkin's lymphoma. British Journal of Cancer. 82(1). 81–84. 8 indexed citations
19.
Beard, S & Adam Finn. (2000). Do we need to boost pertussis immunization within the existing UK vaccination schedule?. Journal of Public Health. 22(3). 349–356. 7 indexed citations
20.
Beard, S, et al.. (1998). A Review of the Use of Current 'Atypical' Antipsychotics in the Treatment of Schizophrenia. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan D. Ross Breakdown of academic impact, for papers by A.L.M. Verbeek Breakdown of academic impact, for papers by Olivier Guérin Breakdown of academic impact, for papers by Samuel Whittle Breakdown of academic impact, for papers by Helen Rodgers Breakdown of academic impact, for papers by Patrícia Caetano Breakdown of academic impact, for papers by Angela Juby Breakdown of academic impact, for papers by Stacey S. Cofield Breakdown of academic impact, for papers by Gillian C. Hall Breakdown of academic impact, for papers by Alan Oglesby
Rankless by CCL
2026